X4 Pharmaceuticals, Inc.
XFOR
$4.02
$0.030.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -71.26% | 1,273.21% | 2,925.73% | 5,721.31% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -71.26% | 1,273.21% | 2,925.73% | 5,721.31% | -- |
| Cost of Revenue | -70.27% | 622.33% | 1,050.51% | 1,978.73% | -- |
| Gross Profit | -71.47% | 1,567.95% | 4,403.82% | 9,121.36% | -- |
| SG&A Expenses | -45.82% | -34.79% | -14.96% | 13.49% | 29.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.60% | -18.52% | -3.05% | 11.68% | 25.46% |
| Operating Income | 18.09% | 41.88% | 28.18% | 14.33% | 1.69% |
| Income Before Tax | -768.20% | -113.13% | -468.53% | -673.29% | 111.58% |
| Income Tax Expenses | -97.85% | -86.77% | 251.76% | 258.33% | 249.46% |
| Earnings from Continuing Operations | -783.12% | -111.48% | -467.43% | -678.36% | 111.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -783.12% | -111.48% | -467.43% | -678.36% | 111.32% |
| EBIT | 18.09% | 41.88% | 28.18% | 14.33% | 1.69% |
| EBITDA | 18.12% | 42.46% | 28.88% | 15.15% | 2.44% |
| EPS Basic | -309.49% | 17.81% | -294.26% | -671.05% | 110.85% |
| Normalized Basic EPS | 65.38% | 79.10% | 46.02% | -12.50% | 35.87% |
| EPS Diluted | -312.02% | 18.20% | -288.01% | -680.37% | 110.72% |
| Normalized Diluted EPS | 65.37% | 79.10% | 46.01% | -12.53% | 35.89% |
| Average Basic Shares Outstanding | 968.96% | 530.30% | 141.07% | 4.42% | 5.88% |
| Average Diluted Shares Outstanding | 967.33% | 530.12% | 141.07% | 4.48% | 6.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |